DXCM - デックスコム （DexCom Inc.）

https://www.investing.com/news/pro/dexcom-receives-investment-bank-analyst-rating-update-3093549

Healthcare stocks are generally more resilient in an uncertain macro backdrop, given the essential nature of products and services offered by the c…

CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.

Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ: DXCM ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with DXCM, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 11 uncommon options trades for DexCom. This isn''t normal. The overall sentiment of these big-money traders is split between 72% bullish and 27%, bearish. Out of all of the special options we uncovered, 4 are puts, for a total amount of $344,068, and 7 are calls, for a total amount of $239,277. What''s The Price Target? Taking into account the Volume and Open Interest on these … Full story available on Benzinga.com

DexCom, Inc. is a global company headquartered in San Diego, California, that focuses on the development, manufacturing, and distribution of continuou

BURNABY, British Columbia — Dexcom, Inc. (NASDAQ: DXCM), – November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers’ Health […]

Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project, as a digital

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Related Stocks: IONQ , RCUS , GTLB , VLD , DXCM ,

DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of the diabetes community to express their unique journey with diabetes in an accessible way – by creating custom Dexcom CGM patches via the newly launched design site that illustrate just how unique each

DUBLIN--(BUSINESS WIRE)--The "Blood Glucose Meters Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com''s offering. The global blood glucose meters market is expected to grow from $2.92 billion in 2020 to $3.99 billion in 2021 at a compound annual growth rate (CAGR) of 36.6%. The market is expected to reach $4.96 billion in 2025 at a CAGR of 5.6%. Major players in the blood glucose meters market are Abbott, Roche, Medtronics, Ascensia

"Global Digital Diabetes Management Market Analysis to 2027" is a detailed and comprehensive report on the market, with a special focus on global market trends. market report provides the market overview, including detailed segmentation and sub-segments. It is expected that

DUBLIN--(BUSINESS WIRE)--The "Remote Patient Monitoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global remote patient monitoring market reached a value of US$ 964 Million in 2020. Looking forward, the publisher expects the global remote patient monitoring market to exhibit strong growth during the next five years. Companies Mentioned Abbott Laboratories AMD Global Telemedicine Inc. B

Digital diabetes devices are the executives'' arrangements are cell phone associated diabetes the board gadgets and programming stages utilized by patients experiencing Type 1, Type 2, and gestational diabetes. Clinical experts likewise utilize these answers to oversee diabetes. Get sample copy

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"